This website uses cookies to enhance the user experience.
V

VAXXINOVA NORWAY AS995 153 637

Research
Limited company
Kong Christian Fredriks plass 3 5006 BERGEN, Norge

VAXXINOVA NORWAY AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
15 years
since Feb 16, 2010
Type
Limited company
VAT registered
Yes
Number of employees
20

Ownership

Number of shares and share classes
100
1 share class
Total number of shareholders
1
person

Financials

Total operating income 2024
14,391,172
NOK
Annual total result 2024
-23,232,304
NOK
Total equity 2024
27,098,999
NOK
Last update: Jun 13, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Board Member-
Board Member-

Others

NameRoleShares
D
DELOITTE AS
Auditor-
B
BDO AS
Accountant-
Last update: Mar 6, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
Ordinary shares
100
100 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year202320222021
Total operating income
14,391,172
12,749,043
10,426,726
Annual Total Result
-23,232,304
-20,230,756
-12,941,261
Total assets
74,336,056
61,932,112
20,628,173
Total liabilities
48,881,811
46,600,810
20,066,116
Total equity
27,098,999
15,331,303
562,058

P&L

Year202320222021
Total operating income
14,391,172
12,749,043
10,426,726
Total operating costs
43,030,990
38,065,129
27,118,674
Operating result
-28,639,818
-25,316,086
-16,691,948
Financial income/costs
-1,805,001
-1,257,180
-6,129
Profit before tax
-30,444,818
-26,573,266
-16,698,077
Total tax & extraordinary income/cost
-7,212,514
-6,342,510
-3,756,816
Annual Total Result
-23,232,304
-20,230,756
-12,941,261

Balance overview

Year202320222021
Total fixed assets
52,759,618
44,116,785
9,270,825
Total current assets
21,576,438
17,815,327
11,357,349
Total assets
74,336,056
61,932,112
20,628,173
Short term debt
14,085,609
33,007,243
3,755,107
Long term debt
34,796,202
13,593,567
16,311,009
Total liabilities
48,881,811
46,600,810
20,066,116
Contributed capital
95,189,372
60,189,372
25,189,372
Retained earnings
-68,090,374
-44,858,069
-24,627,314
Total equity
27,098,999
15,331,303
562,058
Total equity and liabilities
75,980,809
61,932,113
20,628,174

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology